ArticleBMC infectious diseases2026
Magnitude of Tuberculosis, drug resistance patterns and associated factors among presumptive TB patients at five selected public Hospitals, Somali Region, Eastern Ethiopia. Retrospective cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) is a major public health problem worldwide. In 2024, an estimated 10.7 million people fell ill with Tuberculosis worldwide. Emergence of Rifampicin and multi-Drug resistance has posed greater public health threat on control and prevention of TB. Ethiopia is among the top 30 high Tuberculosis burden countries.
objectiveTo determine the Magnitude of Tuberculosis, drug resistance patterns and associated factors among presumptive Tuberculosis patients in Somali Region, Eastern Ethiopia, 2025.
methodsInstitution based retrospective cross-sectional study design was employed from May 10, to June 10, 2025. Total of 460 patient’s cards and registration logs from July - December 2024 were recruited and selected using systematic random sampling technique. Retrospective card review and registers was done. Data were collected using pre-structured checklist. The data were entered into Epi-data version 4.6, exported to and analyzed in SPSS version 25. Bivariate and multi-variable logistic regression analysis was performed to measure the association between dependent and independent variables. P-value < 0.05 was considered statistically significant.
resultThe overall magnitude of Tuberculosis among presumptive TB patients was 20.2%(95%CI: 16–23%) (93/460). It was higher among male patients (24.3%), patients aged between 16 and 30 years (27.1%) and patients with history of TB contact (24.4%). Among the TB confirmed patients, 10.8% (95%CI: 7.9–13.6%), (10/93), were resistant to any first line anti-TB drugs. Magnitude of Rifampicin resistance and multi-drug resistance was 10.8%(95%CI: 7.9–13.6%) and 4.3%(95%CI: 2.4–5.2%) respectively. Drug resistance was higher among previously treated TB patients; 12%(6/50). Being male, AOR (95%CI): 1.89(1.1–3.14, p = 0.012), and having history TB contact; AOR (95%CI):1.8(1.1–2.9, p = 0.02) were statistically associated with Tuberculosis.
conclusionThe magnitude of TB was higher in the study sites. The overall prevalence of drug resistance was also higher; especially previously treated patients. Male sex and having history of TB contact were statistically associated with TB. Early laboratory diagnosis, improving early Treatment initiation and monitoring, and scaling up of TB specimen referral linkage to rapid molecular diagnostics tests sites are highly recommended. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.